1
|
Fielding-Gebhardt H, Kelly SE, Unruh KE, Schmitt LM, Pulver SL, Khemani P, Mosconi MW. Sensorimotor and inhibitory control in aging FMR1 premutation carriers. Front Hum Neurosci 2023; 17:1271158. [PMID: 38034068 PMCID: PMC10687573 DOI: 10.3389/fnhum.2023.1271158] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2023] [Accepted: 10/13/2023] [Indexed: 12/02/2023] Open
Abstract
Aging FMR1 premutation carriers are at risk of developing neurodegenerative disorders, including fragile X-associated tremor/ataxia syndrome (FXTAS), and there is a need to identify biomarkers that can aid in identification and treatment of these disorders. While FXTAS is more common in males than females, females can develop the disease, and some evidence suggests that patterns of impairment may differ across sexes. Few studies include females with symptoms of FXTAS, and as a result, little information is available on key phenotypes for tracking disease risk and progression in female premutation carriers. Our aim was to examine quantitative motor and cognitive traits in aging premutation carriers. We administered oculomotor tests of visually guided/reactive saccades (motor) and antisaccades (cognitive control) in 22 premutation carriers (73% female) and 32 age- and sex-matched healthy controls. Neither reactive saccade latency nor accuracy differed between groups. FMR1 premutation carriers showed increased antisaccade latencies relative to controls, both when considering males and females together and when analyzing females separately. Reduced saccade accuracy and increased antisaccade latency each were associated with more severe clinically rated neuromotor impairments. Findings indicate that together male and female premutation carriers show a reduced ability to rapidly exert volitional control over prepotent responses and that quantitative differences in oculomotor behavior, including control of visually guided and antisaccades, may track with FXTAS - related degeneration in male and female premutation carriers.
Collapse
Affiliation(s)
| | | | - Kathryn E. Unruh
- Life Span Institute, University of Kansas, Lawrence, KS, United States
- Kansas Center for Autism Research and Training (K-CART), University of Kansas, Lawrence, KS, United States
| | - Lauren M. Schmitt
- Division of Behavioral Medicine and Clinical Psychology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, United States
- Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, United States
| | - Stormi L. Pulver
- Division of Autism and Related Disorders, Emory University School of Medicine, Atlanta, GA, United States
| | - Pravin Khemani
- Movement Disorders Program, Swedish Neuroscience Institute, Seattle, WA, United States
| | - Matthew W. Mosconi
- Life Span Institute, University of Kansas, Lawrence, KS, United States
- Kansas Center for Autism Research and Training (K-CART), University of Kansas, Lawrence, KS, United States
- Clinical Child Psychology Program, University of Kansas, Lawrence, KS, United States
| |
Collapse
|
2
|
Phu J, Kalloniatis M. Gaze tracker parameters have little association with visual field metrics of intrasession frontloaded SITA-Faster 24-2 visual field results. Ophthalmic Physiol Opt 2022; 42:973-985. [PMID: 35598152 PMCID: PMC9542222 DOI: 10.1111/opo.13006] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2022] [Revised: 04/27/2022] [Accepted: 04/28/2022] [Indexed: 11/03/2022]
Abstract
PURPOSE To determine the usefulness of Humphrey Field Analyser (HFA) SITA-Faster 24-2 gaze tracker outputs on interpreting intra-visit visual field (VF) result pairs. METHODS Analysis of 1380 right-left eye pairs and 1432 pairs of test 1-test 2 intrasession VF results of patients seen within a university-based glaucoma service was undertaken to understand gaze deviation distributions. Output gaze tracker results were aggregated into total ticks, sum of amplitudes and average amplitudes. Correlations between visual field indices (mean deviation [MD], "events" and overall hill of vision) and independent variables (age and test order) were performed using one eye from each subject. RESULTS There was no association of test order (right-left, test 1-test 2) with eye movements. There was a significant, but weak correlation between eye movements and age (r = 0.16). Correlations of eye movements with MD were driven by more severe MD values. There were no significant correlations between intrasession difference in eye movements and the change in MD, number of "events" and hill of vision, or in the root mean square of sensitivity and total deviation values. There was also no significant correlation between gaze tracker outputs and another commonly used "reliability" metric, false positive rate. CONCLUSIONS Eye movement parameters as currently reported by the HFA do not appear to be correlated with key sensitivity parameters when considering the repeatability of intrasession SITA-Faster 24-2 VF results. Thus, current gaze tracker outputs do not appear to provide clinically meaningful information for interpretation of intra-visit visual field results that cannot already be garnered using other strategies.
Collapse
Affiliation(s)
- Jack Phu
- Centre for Eye Health, University of New South Wales, Kensington, New South Wales, Australia.,School of Optometry and Vision Science, University of New South Wales, Kensington, New South Wales, Australia
| | - Michael Kalloniatis
- Centre for Eye Health, University of New South Wales, Kensington, New South Wales, Australia.,School of Optometry and Vision Science, University of New South Wales, Kensington, New South Wales, Australia
| |
Collapse
|
3
|
Ellmerer P, Peball M, Carbone F, Ritter M, Heim B, Marini K, Valent D, Krismer F, Poewe W, Djamshidian A, Seppi K. Eye Tracking in Patients with Parkinson’s Disease Treated with Nabilone–Results of a Phase II, Placebo-Controlled, Double-Blind, Parallel-Group Pilot Study. Brain Sci 2022; 12:brainsci12050661. [PMID: 35625047 PMCID: PMC9139535 DOI: 10.3390/brainsci12050661] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2022] [Revised: 05/13/2022] [Accepted: 05/13/2022] [Indexed: 12/02/2022] Open
Abstract
The topic of the therapeutic use of cannabinoids in Parkinson’s disease (PD) is broadly discussed and frequently comes up in the outpatient clinic. So far, there are only a few randomized clinical trials assessing the effects of cannabinoids in PD. We are able to demonstrate a reduction in non-motor symptom (NMS) burden after the administration of nabilone. As impairment of attention and working memory have been described earlier as possible side effects, we assess cognitive performance using saccadic paradigms measured by an eye tracker. We do not observe a significant difference in any of the saccadic paradigms between PD patients on placebo versus those treated with nabilone. We, therefore, conclude that top-down inhibitory control is not affected by the tetrahydrocannabinol analogue. Nabilone did not significantly worsen cognitive performance and appears to be safe to use in selected PD patients who suffer from disabling NMS.
Collapse
Affiliation(s)
- Philipp Ellmerer
- Department of Neurology, Medical University Innsbruck, Anichstraße 25, 6020 Innsbruck, Austria; (P.E.); (M.P.); (F.C.); (B.H.); (K.M.); (D.V.); (F.K.); (W.P.); (A.D.)
| | - Marina Peball
- Department of Neurology, Medical University Innsbruck, Anichstraße 25, 6020 Innsbruck, Austria; (P.E.); (M.P.); (F.C.); (B.H.); (K.M.); (D.V.); (F.K.); (W.P.); (A.D.)
| | - Federico Carbone
- Department of Neurology, Medical University Innsbruck, Anichstraße 25, 6020 Innsbruck, Austria; (P.E.); (M.P.); (F.C.); (B.H.); (K.M.); (D.V.); (F.K.); (W.P.); (A.D.)
| | - Marcel Ritter
- Interactive Graphics and Simulation Group, University of Innsbruck, Innrain 52, 6020 Innsbruck, Austria;
| | - Beatrice Heim
- Department of Neurology, Medical University Innsbruck, Anichstraße 25, 6020 Innsbruck, Austria; (P.E.); (M.P.); (F.C.); (B.H.); (K.M.); (D.V.); (F.K.); (W.P.); (A.D.)
| | - Kathrin Marini
- Department of Neurology, Medical University Innsbruck, Anichstraße 25, 6020 Innsbruck, Austria; (P.E.); (M.P.); (F.C.); (B.H.); (K.M.); (D.V.); (F.K.); (W.P.); (A.D.)
| | - Dora Valent
- Department of Neurology, Medical University Innsbruck, Anichstraße 25, 6020 Innsbruck, Austria; (P.E.); (M.P.); (F.C.); (B.H.); (K.M.); (D.V.); (F.K.); (W.P.); (A.D.)
| | - Florian Krismer
- Department of Neurology, Medical University Innsbruck, Anichstraße 25, 6020 Innsbruck, Austria; (P.E.); (M.P.); (F.C.); (B.H.); (K.M.); (D.V.); (F.K.); (W.P.); (A.D.)
| | - Werner Poewe
- Department of Neurology, Medical University Innsbruck, Anichstraße 25, 6020 Innsbruck, Austria; (P.E.); (M.P.); (F.C.); (B.H.); (K.M.); (D.V.); (F.K.); (W.P.); (A.D.)
| | - Atbin Djamshidian
- Department of Neurology, Medical University Innsbruck, Anichstraße 25, 6020 Innsbruck, Austria; (P.E.); (M.P.); (F.C.); (B.H.); (K.M.); (D.V.); (F.K.); (W.P.); (A.D.)
| | - Klaus Seppi
- Department of Neurology, Medical University Innsbruck, Anichstraße 25, 6020 Innsbruck, Austria; (P.E.); (M.P.); (F.C.); (B.H.); (K.M.); (D.V.); (F.K.); (W.P.); (A.D.)
- Correspondence:
| |
Collapse
|